胶质瘤中P170、MGMT、TOPⅡ和GST-π的蛋白表达与化疗药物敏感性的研究  

Expression and clinical significance of P170 ,MGMT,TOPH and GST-π in gliomas

作　　者：孙淑清[1] 徐莉[1] 崔云[1] 李桂林[1] 戴珂[1] 方静宜[1] 岳盛琳[1] 

机构地区：[1]北京市神经外科研究所病理室,100050

出　　处：《中华神经外科杂志》2008年第7期499-502,共4页Chinese Journal of Neurosurgery

摘　　要：目的探讨人脑胶质瘤组织中P170、MGMT、TOPⅡ和GST-π的蛋白表达与临床化疗药物敏感性的关系。方法应用单克隆抗体、免疫组化技术S-P法，对52例低级别（Ⅱ级）和56例高级别（Ⅲ～Ⅳ级）胶质瘤病人组织标本行上述4种指标检测，并分析其术后化疗药物的敏感性。结果胶质瘤组织中P170、MGMT、TOPⅡ和GST-Ⅱ的表达在低级别和高级别胶质瘤之间有统计学意义（P〈0．01），病人术后化疗药物敏感性分析结果显示：大部分P170、TOPⅡ高表达的患者用化疗药物更为有效。结论胶质瘤组织中P170、MGMT、TOPⅡ和GST-Ⅱ的表达高低可指导临床选择化疗药物。Objective To investigate the expressions of P170, MGMT,TOPⅡ and GST-πin gliomas and evaluate their clinical significance. Method The expressions of P170 ,MGMT,TOPII and GST-πwere tested by S-P immunohistochemical technique using monoclonal antibody to their protein in 52cases of low-grade gliomas（ WHO Ⅱ grade） and 56 cases of high-grade gliomas（ WHO Ⅲ-Ⅳ grade） and anahysed the sensitivity chemotherapy drugs in chinical. Results The expressions of P170,MGMT,TOPⅡ and GST-πin gliomas had significant differences between low-grade and high-grade gliomas （ P 〈 0.01 ）. chemotherapy drugs was choiced respectively. Condusions Combining detection of P170, MGMT,TOPll and GST-π is benefit for the choice of the chemotherapy drugs choicing corrective chemotherapy drugs after operation can reduce mortality of glioma patients.

关 键 词：神经胶质瘤 蛋白质类化疗药 抗肿瘤联合化疗方案 

分 类 号：R686[医药卫生—骨科学]